MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.

Status:
NOT_YET_RECRUITING

Trial end date:
2027-02-20

Target enrollment:

Participant gender:

This study will evaluate the safety and efficacy of MSC303 in patients with Immune glomerular diseases.

PHASE1

Shanghai Changzheng Hospital